| Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study E Martinez, A Mocroft, MA García-Viejo, JB Pérez-Cuevas, JL Blanco, ... The Lancet 357 (9256), 592-598, 2001 | 560 | 2001 |
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients M Laguno, J Murillas, JL Blanco, E Martínez, R Miquel, ... Aids 18 (13), 27-36, 2004 | 509 | 2004 |
| COVID-19 in patients with HIV: clinical case series JL Blanco, J Ambrosioni, F Garcia, E Martínez, A Soriano, J Mallolas, ... The lancet HIV 7 (5), e314-e316, 2020 | 507 | 2020 |
| Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy E Martínez, JL Blanco, JA Arnaiz, JB Pérez-Cuevas, A Mocroft, A Cruceta, ... Aids 15 (10), 1261-1268, 2001 | 468 | 2001 |
| Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label … JK Rockstroh, M Nelson, C Katlama, J Lalezari, J Mallolas, M Bloch, ... The lancet HIV 2 (8), e319-e327, 2015 | 408 | 2015 |
| Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus … M Sulkowski, C Hezode, J Gerstoft, JM Vierling, J Mallolas, S Pol, ... The Lancet 385 (9973), 1087-1097, 2015 | 370 | 2015 |
| Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and … J Berenguer, J Álvarez‐Pellicer, PM Martín, J López‐Aldeguer, ... Hepatology 50 (2), 407-413, 2009 | 358 | 2009 |
| Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus—Infected Patients with Chronic Hepatitis C: A European Collaborative Study L Martín-Carbonero, Y Benhamou, M Puoti, J Berenguer, J Mallolas, ... Clinical Infectious Diseases 38 (1), 128-133, 2004 | 313 | 2004 |
| A prospective study of the risk of tuberculosis among HIV-infected patients A Guelar, JM Gatell, J Verdejo, D Podzamczer, L Lozano, E Aznar, ... Aids 7 (10), 1345-1350, 1993 | 274 | 1993 |
| Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count F García, E de Lazzari, M Plana, P Castro, G Mestre, M Nomdedeu, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 36 (2), 702-713, 2004 | 268 | 2004 |
| Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy A Suy, E Martínez, O Coll, M Lonca, M Palacio, E de Lazzari, M Larrousse, ... Aids 20 (1), 59-66, 2006 | 243 | 2006 |
| Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: a randomized controlled comparison with zidovudine monotherapy C Katlama, D Ingrand, C Loveday, N Clumeck, J Mallolas, S Staszewski, ... Jama 276 (2), 118-125, 1996 | 235 | 1996 |
| Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind … M Sulkowski, S Pol, J Mallolas, H Fainboim, C Cooper, J Slim, A Rivero, ... The Lancet infectious diseases 13 (7), 597-605, 2013 | 225 | 2013 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 209 | 2018 |
| Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine UA Walker, J Bäuerle, M Laguno, J Murillas, S Mauss, G Schmutz, ... Hepatology 39 (2), 311-317, 2004 | 209 | 2004 |
| Sustained Virological response to interferon plus Ribavirin reduces non–liver-related mortality in patients Coinfected with HIV and hepatitis C virus J Berenguer, E Rodríguez, P Miralles, MA Von Wichmann, ... Clinical infectious diseases 55 (5), 728-736, 2012 | 201 | 2012 |
| Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study M Martin, E Del Cacho, C Codina, M Tuset, E De Lazzari, J Mallolas, ... AIDS research and human retroviruses 24 (10), 1263-1268, 2008 | 195 | 2008 |
| Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos (t) ide reverse … JR Arribas, PM Girard, R Landman, J Pich, J Mallolas, ... The Lancet Infectious Diseases 15 (7), 785-792, 2015 | 194 | 2015 |
| High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors E Martínez, J Gatell, Y Morán, E Aznar, E Buira, A Guelar, J Mallolas, ... Clinical infectious diseases 27 (6), 1510-1513, 1998 | 192 | 1998 |
| Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy E Martínez, MA García-Viejo, JL Blanco, L Bianchi, E Buira, I Conget, ... Clinical infectious diseases 31 (5), 1266-1273, 2000 | 190 | 2000 |
